Effects of specific treatment on parasitological and histopathological parameters in mice infected with different

M J O Toledo1, M T Bahia, V M Veloso

  • 1Departamento de Análises Clínicas, Centro de Ciências da Saúde, Bloco I-90, Universidade Estadual de Maringá, Av. Colombo, 5790, 87020-900, Maringá, PR. mjotoledo@uem.br

Insights

Benznidazole effectively reduced Trypanosoma cruzi infection markers in mice across different genotypes. Phylogenetic differences among T. cruzi strains influence treatment outcomes, highlighting the need for personalized chemotherapy.

Area of Science:

  • Parasitology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Trypanosoma cruzi causes Chagas disease, a neglected tropical illness.
  • The parasite exhibits significant phylogenetic diversity, impacting disease progression and treatment efficacy.
  • Understanding genotype-specific responses to antiparasitic drugs is crucial for effective Chagas disease management.

Purpose of the Study:

  • To evaluate the impact of benznidazole and itraconazole on parasitological and histopathological parameters in mice infected with diverse Trypanosoma cruzi clonal genotypes.
  • To determine if T. cruzi phylogenetic divergence influences treatment outcomes.

Main Methods:

  • Experimental infection of BALB/c mice with 20 T. cruzi cloned stocks representing genotypes T. cruzi I and T. cruzi II.
  • Treatment groups included benznidazole, itraconazole, and untreated controls.
  • Analysis of seven parameters: parasitaemia curves (acute and chronic phases) and histopathological lesions (acute phase).

Main Results:

  • Benznidazole significantly reduced patent period, peak parasitaemia, and parasite load across all tested T. cruzi genotypes.
  • Lower parasitaemia and tissue parasitism were observed with benznidazole for specific genotypes (19 and 32).
  • Itraconazole demonstrated a less pronounced effect compared to benznidazole.

Conclusions:

  • Phylogenetic diversity among T. cruzi clonal genotypes is a critical factor in chemotherapy effectiveness.
  • Benznidazole is a promising treatment option, but its efficacy can vary depending on the parasite genotype.
  • Future research and treatment strategies for Chagas disease should consider T. cruzi phylogenetic divergence.